| Peer-Reviewed

An Evaluation of Pain Response Between Single Fraction Radiotherapy Versus 10 Fractions RT in Metastatic Vertebral Bone Disease: A Quasi Experimental Study

Received: 15 February 2022     Accepted: 4 March 2022     Published: 15 March 2022
Views:       Downloads:
Abstract

The prognosis of bone metastasis is poor, with median survival measured in months, not years. Treatment remains an important issue to alleviate the complications and sufferings of the patients. This study was aimed to evaluate the pain response between single versus multiple fraction radiotherapy in metastatic vertebral bone disease. In this prospective quasi experimental study, the sample consisted of 60 patients of Oncology Dept., KYAMCH. Purposive sampling method was used. The respondents were divided into 2 arms, Arm A consisted of 30 patients, receiving 800 cGy single fraction RT, and Arm B consisted 30 patients who received 3000 cGy multiple fractions RT. The data were collected using a semi-structured questionnaire, which was constructed in line with the reviewed literature along with RECIST (Response Evaluation in Solid Tumor) criteria, VAS (Visual Analogue Scale) after 4 weeks of RT completion and Radiation Therapy Oncology Group (RTOG) criteria. Mean age of Arm A was 43.73 years, and Arm B was 46.8 years. Lung cancer was the leading cancer in both arms, 43.3% and 36.6% respectively. Adenocarcinoma was the commonest histopathological type of cancer found in both arms, 39.9% and 36.6% respectively. To determine associations, Chi-Square tests were done. For Arm A, 66.6% initially presented with severe pain, 23.31% with moderate and 10% with mild pain. In arm B 59.94%, 33.3% and 6.66% patients presented with severe, moderate and mild pain respectively. One month after completion of RT, pain significantly reduced in patients of both arms with a p value of < .001. No significant difference was observed between 8 Gy in single fraction versus 30 Gy in 10 fractions radiotherapy in the management of secondary bone tumour. It was found, both the radiation fractionation schedule for the management of secondary bone tumour are equally effective. More patients can be provided with the desired treatment with shorter period of time. It will certainly ease the economic burden on the patients as well as on the country.

Published in Journal of Cancer Treatment and Research (Volume 10, Issue 1)
DOI 10.11648/j.jctr.20221001.11
Page(s) 1-7
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Pain Response, Radiotherapy, Metastatic Vertebral Bone Disease, Cancer

References
[1] Asdourian PL, Weidenbaum MA, DeWald RL, Hammerberg KW, Ramsey RG. The pattern of vertebral involvement in metastatic vertebral breast cancer. Clinical orthopaedics and related research. 1990 Jan 1 (250): 164-70.
[2] Beals RK, Lawton GD, Snell WE. Prophylactic internal fixation of the femur in metastatic breast cancer. Cancer. 1971; 28 (5): 1350-4.
[3] Cheal EJ, Hipp JA, Hayes WC. Evaluation of finite element analysis for prediction of the strength reduction due to metastatic lesions in the femoral neck. Journal of biomechanics. 1993 Mar 1; 26 (3): 251-64.
[4] Cleeland CS. The measurement of pain from metastatic bone disease: capturing the patient's experience. Clinical Cancer Research. 2006 Oct 15; 12 (20): 6236s-42s.
[5] Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ. Pain and its treatment in outpatients with metastatic cancer. New England Journal of Medicine. 1994 Mar 3; 330 (9): 592-6.
[6] Coleman RE. Skeletal complications of malignancy. Cancer: Interdisciplinary International Journal of the American Cancer Society. 1997 Oct 15; 80 (S8): 1588-94.
[7] Coleman RE, Rubens R. The clinical course of bone metastases from breast cancer. British journal of cancer. 1987 Jan; 55 (1): 61-6.
[8] Daldrup-Link HE, Franzius C, Link TM, Laukamp D, Sciuk J, Jürgens H, Schober O, Rummeny EJ. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. American Journal of Roentgenology. 2001 Jul; 177 (1): 229-36.
[9] Eriksen EF. Cellular mechanisms of bone remodeling. Reviews in Endocrine and Metabolic Disorders. 2010 Dec; 11 (4): 219-27.
[10] Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single-and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. Journal of Nuclear Medicine. 2006 Feb 1; 47 (2): 287-97.
[11] Fidler M. Incidence of fracture through metastases in long bones. Acta Orthopaedica Scandinavica. 1981 Jan 1; 52 (6): 623-7.
[12] Flickinger FW, Sanal SM. Bone marrow MRI: techniques and accuracy for detecting breast cancer metastases. Magnetic resonance imaging. 1994 Jan 1; 12 (6): 829-35.
[13] Fujimoto R, Higashi T, Nakamoto Y, Hara T, Lyshchik A, Ishizu K, Kawashima H, Kawase S, Fujita T, Saga T, Togashi K. Diagnostic accuracy of bone metastases detection in cancer patients: comparison between bone scintigraphy and whole-body FDG-PET. Annals of nuclear medicine. 2006 Jul; 20 (6): 399-408.
[14] Goblirsch MJ, Zwolak PP, Clohisy DR. Biology of bone cancer pain. Clinical cancer research. 2006 Oct 15; 12 (20): 6231s-5s.
[15] Gurney H, Larcos G, McKay M, Kefford R, Langlands A. Bone metastases in hypernephroma. Frequency of scapular involvement. Cancer. 1989 Oct 1; 64 (7): 1429-31.
[16] Harrington KD. Orthopaedic management of extremity and pelvic lesions. Clinical orthopaedics and related research. 1995 Mar 1 (312): 136-47.
[17] Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. Journal of Clinical Oncology. 2004 Jul 15; 22 (14): 2942-53.
[18] Hoskin, P. J., Stratford, M. R. L., Folkes, L. K., Regan, J. and Yarnold, J. R., 2000. Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. The Lancet, 355 (9213), pp. 1428-1429.
[19] Hitchins RN, Philip PA, Wignall B, Newlands ES, Begent RH, Rustin GJ, Bagshawe KD. Bone disease in testicular and extragonadal germ cell tumours. British journal of cancer. 1988 Dec; 58 (6): 793-6.
[20] Khan L, Uy C, Nguyen J, Chow E, Zhang L, Zeng L, Salvo N, Culleton S, Jon F, Wong K, Danjoux C. Self-reported rates of sleep disturbance in patients with symptomatic bone metastases attending an outpatient radiotherapy clinic. Journal of palliative medicine. 2011 Jun 1; 14 (6): 708-14.
[21] Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling—emerging insights into the pathophysiology of osteoporosis. New England journal of medicine. 1995 Feb 2; 332 (5): 305-11.
[22] Matsuyama T, Tsukamoto N, Imachi M, Nakano H. Bone metastasis from cervix cancer. Gynecologic oncology. 1989 Jan 1; 32 (1): 72-5.
[23] Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain. 2001 Sep 1; 93 (3): 247-57.
[24] Mirels HI. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clinical orthopaedics and related research. 1989 Dec 1 (249): 256-64.
[25] Morris C. Survival in patients operated on for pathologic fracture: implications for end-of-life orthopedic care. J Clin Oncol. 2005; 23: 6072-82.
[26] Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. Journal of Clinical Oncology. 1991 Mar; 9 (3): 509-24.
[27] Nguyen J, Cramarossa G, Bruner D, Chen E, Khan L, Leung A, Lutz S, Chow E. A literature review of symptom clusters in patients with breast cancer. Expert review of pharmacoeconomics & outcomes research. 2011 Oct 1; 11 (5): 533-9.
[28] Ohta M, Tokuda Y, Suzuki Y, Kubota M, Makuuchi H, Tajima T, Nasu S, Yasuda S, Shohtsu A. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nuclear medicine communications. 2001 Aug 1; 22 (8): 875-9.
[29] Parmar A, Mehta M, Yadav R, Parikh A, Suryanarayana U. Single Fraction versus Multi Fraction Radiotherapy Treatment Schedules for Management of Painful Bone Metastasis.
[30] Perez C, Brady L. Principles and practice of radiation oncology. Journal of Pediatric Hematology/Oncology. 1999 Nov 1; 21 (6): 560.
[31] Ratanatharathorn V, Powers WE, Moss WT, Perez CA. Bone metastasis: review and critical analysis of random allocation trials of local field treatment. International Journal of Radiation Oncology Biology Physics. 1999 Apr 1; 44 (1): 1-8.
[32] Roodman GD. Mechanisms of bone metastasis. New England journal of medicine. 2004 Apr 15; 350 (16): 1655-64.
[33] Schmidt GP, Schoenberg SO, Reiser MF, Baur-Melnyk A. Whole-body MR imaging of bone marrow. European journal of radiology. 2005 Jul 1; 55 (1): 33-40.
[34] Sim FH, Frassica FJ, Chao EY. Orthopaedic management using new devices and prostheses. Clinical orthopaedics and related research. 1995 Mar 1 (312): 160-72.
[35] Singh D, Yi WS, Brasacchio RA, Muhs AG, Smudzin T, Williams JP, Messing E, Okunieff P. Is there a favorable subset of patients with prostate cancer who develop oligometastases? International Journal of Radiation Oncology Biology Physics. 2004 Jan 1; 58 (1): 3-10.
[36] Smith HS. Painful osseous metastases. Pain physician. 2011 Jul 1; 14 (4): E373-403.
[37] Steinmetz MP, Mekhail A, Benzel EC. Management of metastatic tumors of the spine: strategies and operative indications. Neurosurgical Focus. 2001 Dec 1; 11 (6): 1-6.
[38] Van der Linden YM, Dijkstra PD, Kroon HM, Lok JJ, Noordijk EM, Leer JW, Marijnen CA. Comparative analysis of risk factors for pathological fracture with femoral metastases: results based on a randomised trial of radiotherapy. The Journal of bone and joint surgery. British volume. 2004 May; 86 (4): 566-73.
[39] Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain. 1995 Oct 1; 63 (1): 65-76.
[40] Zetter BR. The cellular basis of site-specific tumor metastasis. New England Journal of Medicine. 1990 Mar 1; 322 (9): 605-12.
[41] Majumder D, Chatterjee D, Bandyopadhyay A, Mallick SK, Sarkar SK, Majumdar A. Single fraction versus multiple fraction radiotherapy for palliation of painful vertebral bone metastases: A prospective study. Indian Journal of Palliative Care. 2012 Sep; 18 (3): 202.
Cite This Article
  • APA Style

    Bhaskar Chakraborty, Tarim Mahmood, Maksud Hassan Binoy. (2022). An Evaluation of Pain Response Between Single Fraction Radiotherapy Versus 10 Fractions RT in Metastatic Vertebral Bone Disease: A Quasi Experimental Study. Journal of Cancer Treatment and Research, 10(1), 1-7. https://doi.org/10.11648/j.jctr.20221001.11

    Copy | Download

    ACS Style

    Bhaskar Chakraborty; Tarim Mahmood; Maksud Hassan Binoy. An Evaluation of Pain Response Between Single Fraction Radiotherapy Versus 10 Fractions RT in Metastatic Vertebral Bone Disease: A Quasi Experimental Study. J. Cancer Treat. Res. 2022, 10(1), 1-7. doi: 10.11648/j.jctr.20221001.11

    Copy | Download

    AMA Style

    Bhaskar Chakraborty, Tarim Mahmood, Maksud Hassan Binoy. An Evaluation of Pain Response Between Single Fraction Radiotherapy Versus 10 Fractions RT in Metastatic Vertebral Bone Disease: A Quasi Experimental Study. J Cancer Treat Res. 2022;10(1):1-7. doi: 10.11648/j.jctr.20221001.11

    Copy | Download

  • @article{10.11648/j.jctr.20221001.11,
      author = {Bhaskar Chakraborty and Tarim Mahmood and Maksud Hassan Binoy},
      title = {An Evaluation of Pain Response Between Single Fraction Radiotherapy Versus 10 Fractions RT in Metastatic Vertebral Bone Disease: A Quasi Experimental Study},
      journal = {Journal of Cancer Treatment and Research},
      volume = {10},
      number = {1},
      pages = {1-7},
      doi = {10.11648/j.jctr.20221001.11},
      url = {https://doi.org/10.11648/j.jctr.20221001.11},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20221001.11},
      abstract = {The prognosis of bone metastasis is poor, with median survival measured in months, not years. Treatment remains an important issue to alleviate the complications and sufferings of the patients. This study was aimed to evaluate the pain response between single versus multiple fraction radiotherapy in metastatic vertebral bone disease. In this prospective quasi experimental study, the sample consisted of 60 patients of Oncology Dept., KYAMCH. Purposive sampling method was used. The respondents were divided into 2 arms, Arm A consisted of 30 patients, receiving 800 cGy single fraction RT, and Arm B consisted 30 patients who received 3000 cGy multiple fractions RT. The data were collected using a semi-structured questionnaire, which was constructed in line with the reviewed literature along with RECIST (Response Evaluation in Solid Tumor) criteria, VAS (Visual Analogue Scale) after 4 weeks of RT completion and Radiation Therapy Oncology Group (RTOG) criteria. Mean age of Arm A was 43.73 years, and Arm B was 46.8 years. Lung cancer was the leading cancer in both arms, 43.3% and 36.6% respectively. Adenocarcinoma was the commonest histopathological type of cancer found in both arms, 39.9% and 36.6% respectively. To determine associations, Chi-Square tests were done. For Arm A, 66.6% initially presented with severe pain, 23.31% with moderate and 10% with mild pain. In arm B 59.94%, 33.3% and 6.66% patients presented with severe, moderate and mild pain respectively. One month after completion of RT, pain significantly reduced in patients of both arms with a p value of < .001. No significant difference was observed between 8 Gy in single fraction versus 30 Gy in 10 fractions radiotherapy in the management of secondary bone tumour. It was found, both the radiation fractionation schedule for the management of secondary bone tumour are equally effective. More patients can be provided with the desired treatment with shorter period of time. It will certainly ease the economic burden on the patients as well as on the country.},
     year = {2022}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - An Evaluation of Pain Response Between Single Fraction Radiotherapy Versus 10 Fractions RT in Metastatic Vertebral Bone Disease: A Quasi Experimental Study
    AU  - Bhaskar Chakraborty
    AU  - Tarim Mahmood
    AU  - Maksud Hassan Binoy
    Y1  - 2022/03/15
    PY  - 2022
    N1  - https://doi.org/10.11648/j.jctr.20221001.11
    DO  - 10.11648/j.jctr.20221001.11
    T2  - Journal of Cancer Treatment and Research
    JF  - Journal of Cancer Treatment and Research
    JO  - Journal of Cancer Treatment and Research
    SP  - 1
    EP  - 7
    PB  - Science Publishing Group
    SN  - 2376-7790
    UR  - https://doi.org/10.11648/j.jctr.20221001.11
    AB  - The prognosis of bone metastasis is poor, with median survival measured in months, not years. Treatment remains an important issue to alleviate the complications and sufferings of the patients. This study was aimed to evaluate the pain response between single versus multiple fraction radiotherapy in metastatic vertebral bone disease. In this prospective quasi experimental study, the sample consisted of 60 patients of Oncology Dept., KYAMCH. Purposive sampling method was used. The respondents were divided into 2 arms, Arm A consisted of 30 patients, receiving 800 cGy single fraction RT, and Arm B consisted 30 patients who received 3000 cGy multiple fractions RT. The data were collected using a semi-structured questionnaire, which was constructed in line with the reviewed literature along with RECIST (Response Evaluation in Solid Tumor) criteria, VAS (Visual Analogue Scale) after 4 weeks of RT completion and Radiation Therapy Oncology Group (RTOG) criteria. Mean age of Arm A was 43.73 years, and Arm B was 46.8 years. Lung cancer was the leading cancer in both arms, 43.3% and 36.6% respectively. Adenocarcinoma was the commonest histopathological type of cancer found in both arms, 39.9% and 36.6% respectively. To determine associations, Chi-Square tests were done. For Arm A, 66.6% initially presented with severe pain, 23.31% with moderate and 10% with mild pain. In arm B 59.94%, 33.3% and 6.66% patients presented with severe, moderate and mild pain respectively. One month after completion of RT, pain significantly reduced in patients of both arms with a p value of < .001. No significant difference was observed between 8 Gy in single fraction versus 30 Gy in 10 fractions radiotherapy in the management of secondary bone tumour. It was found, both the radiation fractionation schedule for the management of secondary bone tumour are equally effective. More patients can be provided with the desired treatment with shorter period of time. It will certainly ease the economic burden on the patients as well as on the country.
    VL  - 10
    IS  - 1
    ER  - 

    Copy | Download

Author Information
  • Oncology, Ahsania Cancer Mission Hospital, Dhaka, Bangladesh

  • Department of Maternal and Child Health, NIPSOM, Dhaka, Bangladesh

  • Biotech, Beacon Pharmaceuticals Ltd, Dhaka, Bangladesh

  • Sections